$LLY said Tuesday that its cancer drug Verzenio succeeded in preventing breast-cancer recurrence in a study of the kind that $PFE big seller Ibrance failed in May. The Lilly news will enhance doctors’ views of its drug as Verzenio tries to catch up with Pfizer’s category leader.